Outcomes in COVID-19 clevudine studies

0 0.5 1 1.5+ All studies -744% 1 61 Improvement, Studies, Patients Relative Risk Viral clearance 27% 1 61 RCTs -744% 1 61 Late -744% 1 61 Clevudine for COVID-19 c19early.org November 2025 Favorsclevudine Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ BK-CLV-201 Song (SB RCT) -744% 8.44 [0.49-146] no recov. 5/41 0/20 Improvement, RR [CI] Treatment Control Song (DB RCT) unknown, >4 years late 104 (total) Tau​2 = 0.00, I​2 = 0.0%, p = 0.14 Late treatment -744% 8.44 [0.49-146] 5/41 0/20 744% higher risk All studies -744% 8.44 [0.49-146] 5/41 0/20 744% higher risk 1 clevudine COVID-19 study (+1 unreported RCT) c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.14 Effect extraction pre-specified(most serious outcome) Favors clevudine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ BK-CLV-201 Song (SB RCT) -744% 8.44 [0.49-146] no recov. 5/41 0/20 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.14 Late treatment -744% 8.44 [0.49-146] 5/41 0/20 744% higher risk All studies -744% 8.44 [0.49-146] 5/41 0/20 744% higher risk 1 clevudine COVID-19 recovery result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.14 Favors clevudine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ BK-CLV-201 Song (SB RCT) 27% 0.73 [0.36-1.50] viral+ 12/41 8/20 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.4 Late treatment 27% 0.73 [0.36-1.50] 12/41 8/20 27% lower risk All studies 27% 0.73 [0.36-1.50] 12/41 8/20 27% lower risk 1 clevudine COVID-19 viral clearance result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.4 Favors clevudine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ BK-CLV-201 Song (SB RCT) -744% 8.44 [0.49-146] no recov. 5/41 0/20 Improvement, RR [CI] Treatment Control Song (DB RCT) unknown, >4 years late 104 (total) Tau​2 = 0.00, I​2 = 0.0%, p = 0.14 Late treatment -744% 8.44 [0.49-146] 5/41 0/20 744% higher risk All studies -744% 8.44 [0.49-146] 5/41 0/20 744% higher risk 1 clevudine COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.14 Effect extraction pre-specified(most serious outcome) Favors clevudine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ BK-CLV-201 Song (SB RCT) -744% 8.44 [0.49-146] no recov. 5/41 0/20 Improvement, RR [CI] Treatment Control BK-CLV-201 Song (SB RCT) 27% 0.73 [0.36-1.50] viral+ 12/41 8/20 BK-CLV-201 Song (SB RCT) -22% 1.22 [0.65-2.27] viral+ 20/41 8/20 BK-CLV-201 Song (SB RCT) 6% 0.94 [0.68-1.30] viral+ 29/41 15/20 BK-CLV-201 Song (SB RCT) 5% 0.95 [0.78-1.15] viral+ 35/41 18/20 Clevudine COVID-19 outcomes c19early.org November 2025 Favors clevudine Favors control